# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K202525   
B Applicant Abbott Laboratories Diagnostic Division   
C Proprietary and Established Names Alinity i STAT High Sensitivity Troponin-I   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MMI</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1215 -CreatinePhosphokinase/Creatine Kinase OrIsoenzymes TestSystem</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Cardiac Troponin I (cTnI)   
C Type of Test: Quantitative Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The Alinity i STAT High Sensitivity Troponin-I assay is a chemiluminescent microparticle immunoassay (CMIA) used for the quantitative determination of cardiac troponin I (cTnI) in human plasma (lithium heparin) on the Alinity i system.

The Alinity i STAT High Sensitivity Troponin-I assay is to be used as an aid in the diagnosis of myocardial infarction (MI).

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only For in vitro diagnostic use

D Special Instrument Requirements:

Alinity i System

# IV Device/System Characteristics:

# A Device Description:

The following are needed to conduct testing:

Alinity i STAT High Sensitivity Troponin-I Reagent Kit which contains:

Microparticles: 1 bottle $\mathrm { 6 . 6 { m L } }$ per 100 test cartridge / $3 3 . 8 \mathrm { m L }$ per 600 test cartridge). Antitroponin I (mouse, monoclonal) coated microparticles in TRIS buffer with protein (bovine) stabilizer. Minimum concentration: $0 . 0 3 5 \%$ solids. Preservative: ProClin 300.

Conjugate: 1 bottle $( 6 . 1 \mathrm { m L }$ per 100 test cartridge $^ { \prime } 3 3 . 8 \mathrm { m L }$ per 600 test cartridge). Anti-troponin I (mouse-human chimeric, monoclonal) acridinium-labeled conjugate in MES buffer with protein (bovine) stabilizer and human IgG. Minimum concentration: 0.1 $\mathrm { m g / L }$ . Preservative: ProClin 300.

The following are also required to conduct testing but are not provided with the kit:

• Alinity i STAT High Sensitivity Troponin-I assay file 04Z2101 Alinity i STAT High Sensitivity Troponin-I Calibrators   
• 04Z2110 Alinity i STAT High Sensitivity Troponin-I Controls or other control material containing cTnI   
• Alinity Pre-Trigger Solution   
• Alinity Trigger Solution   
• Alinity i-series Concentrated Wash Buffer   
• 09P1540 Alinity i Multi-Assay Manual Diluent

# B Principle of Operation:

The Alinity i STAT High Sensitivity Troponin-I assay is an automated, two-step immunoassay for the quantitative determination of cTnI in human plasma (lithium heparin) using CMIA technology.

Sample and anti-troponin I antibody-coated coated paramagnetic microparticles are combined and incubated. The cTnI present in the sample binds to the anti-troponin I coated microparticles. The mixture is washed. Anti-troponin I acridinium-labeled conjugate is added to create a reaction mixture and incubated. Following a wash cycle, Pre-Trigger and Trigger Solutions are added.

The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of cTnI in the sample and the RLU detected by the system optics.

# V Substantial Equivalence Information:

A Predicate Device Name(s): ARCHITECT STAT High Sensitivity Troponin-I   
B Predicate 510(k) Number(s): K191595   
C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K202525</td><td colspan="1" rowspan="1">K191595</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Alinity i STAT HighSensitivity Troponin-I</td><td colspan="1" rowspan="1">ARCHITECT STATHigh SensitivityTroponin-I</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The assay is for thequantitativedetermination of cardiactroponin I used as anaid in the diagnosis ofmyocardial infarction.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Plasma (lithiumheparin)</td><td colspan="1" rowspan="1">Plasma (dipotassium[K2] EDTA)</td></tr><tr><td colspan="1" rowspan="1">99th PercentileCutoff / Expected Valuesfrom Apparently HealthyIndividuals(ng/L, pg/mL)</td><td colspan="1" rowspan="1">Female: 14Male: 35Overall: 27</td><td colspan="1" rowspan="1">Female: 17Male: 35Overall: 28</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Clinical and Laboratory Standards Institute (CLSI) EP05-A3, Evaluation of Precision of   
Quantitative Measurement Procedures; Approved Guideline–Third Edition   
CLSI EP07, 3rd ed., Interference Testing in Clinical Chemistry   
CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement   
Procedures; Approved Guideline–Second Edition   
CLSI EP28-A3c, Defining, Establishing, and Verifying Reference Intervals in the Clinical   
Laboratory; Approved Guideline–Third Edition   
CLSI EP35, $1 ^ { \mathrm { s t } }$ ed., Assessment of Equivalence or Suitability of Specimen Types for Medica   
Laboratory Measurement Procedures

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

A study was performed using 1 lot of the Alinity i STAT High Sensitivity Troponin-I reagent, 1 lot of the Alinity i STAT High Sensitivity Troponin-I Calibrators, and 1 lot of the Alinity i STAT High Sensitivity Troponin-I Controls. The study was performed using fresh, native lithium heparin plasma specimens within each of 5 concentration ranges $( > 3$ to 6 $\mathrm { n g / L }$ , 10 to $2 0 \mathrm { n g / L }$ , 30 to $5 0 \mathrm { n g / L }$ , and 100 to $3 0 0 \mathrm { n g / L }$ , and 1000 to $4 5 0 0 \mathrm { n g / L }$ ). Testing for each sample was performed within the 8-hour stability claim for patient samples. The study was performed over a minimum of 3 days. Each specimen was stored at room temperature and tested in duplicate, twice in one day, on each of 3 instruments (for a total of 12 replicates per sample) within 8 hours of collection. Within-laboratory precision includes within-run and between-run variability. Reproducibility includes within-run, between-run, and betweeninstrument variance components.

<table><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">n</td><td colspan="1" rowspan="2">Mean(ng/L)</td><td colspan="2" rowspan="1">Within-Run</td><td colspan="2" rowspan="1">Between-Run</td><td colspan="2" rowspan="1">Within-Laboratory</td><td colspan="2" rowspan="1">Reproducibility</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">Sample 1</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">6.2</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">6.2</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">8.7</td></tr><tr><td colspan="1" rowspan="1">Sample 2</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">12.7</td></tr><tr><td colspan="1" rowspan="1">Sample 3</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">8.0</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">8.4</td></tr><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">n</td><td colspan="1" rowspan="1">Mean</td><td colspan="2" rowspan="1">Within-Run</td><td colspan="2" rowspan="1">Between-Run</td><td colspan="2" rowspan="1">Within-Laboratory</td><td colspan="2" rowspan="1">Reproducibility</td></tr><tr><td colspan="1" rowspan="1">(ng/L)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">Sample 4</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">13.6</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.61</td><td colspan="1" rowspan="1">4.5</td></tr><tr><td colspan="1" rowspan="1">Sample 5</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">13.9</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.7</td></tr><tr><td colspan="1" rowspan="1">Sample 6</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">15.1</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">Sample 7</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">18.2</td><td colspan="1" rowspan="1">0.82</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.82</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.82</td><td colspan="1" rowspan="1">4.5</td></tr><tr><td colspan="1" rowspan="1">Sample 8</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">20.2</td><td colspan="1" rowspan="1">0.66</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.66</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">0.74</td><td colspan="1" rowspan="1">3.7</td></tr><tr><td colspan="1" rowspan="1">Sample 9</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">36.9</td><td colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">1.17</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">Sample 10</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">46.7</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">Sample 11</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">51.6</td><td colspan="1" rowspan="1">1.22</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">1.63</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">1.63</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">Sample 12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">172.6</td><td colspan="1" rowspan="1">4.51</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">5.53</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">7.14</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">7.14</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">Sample 13</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">233.0</td><td colspan="1" rowspan="1">5.00</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">9.18</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">10.45</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">10.45</td><td colspan="1" rowspan="1">4.5</td></tr><tr><td colspan="1" rowspan="1">Sample 14</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">300.0</td><td colspan="1" rowspan="1">11.00</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">5.61</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">12.35</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">12.35</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">Sample 15</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">1228.3</td><td colspan="1" rowspan="1">29.03</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">45.23</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">53.74</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">53.74</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">Sample 16</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">1974.6</td><td colspan="1" rowspan="1">49.46</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">57.97</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">76.21</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">76.21</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">Sample 17</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">2871.4</td><td colspan="1" rowspan="1">72.86</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">85.31</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">112.19</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">112.19</td><td colspan="1" rowspan="1">3.9</td></tr></table>

A second study was performed following the recommendations in the EP05-A3 guideline. Testing was conducted using 3 lots of the Alinity i STAT High Sensitivity Troponin-I reagent, 2 lots of the Alinity i STAT High Sensitivity Troponin-I Calibrators, and 1 lot of the Alinity i STAT High Sensitivity Troponin-I Controls using 2 instruments. Three controls were tested in duplicate, twice per day over 20 days. Within-laboratory variability contains within-run, between-run, and between-day variability. Patient samples can only be stored for 8 hours at room temperature; therefore, 20-day precision studies were conducted with quality control materials.

<table><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">Instrument</td><td colspan="1" rowspan="2">ReagentLot</td><td colspan="1" rowspan="2">N</td><td colspan="1" rowspan="2">Mean(ng/L)</td><td colspan="2" rowspan="1">Within-Run</td><td colspan="2" rowspan="1">Within-Laboratory(Total)</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="6">Low Control</td><td colspan="1" rowspan="3">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">20.1</td><td colspan="1" rowspan="1">0.59</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">0.87</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">20.0</td><td colspan="1" rowspan="1">0.61</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">4.5</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">22.0</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">1.13</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="3">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">19.6</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">19.9</td><td colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">0.81</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">18.3</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">0.77</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="6">MediumControl</td><td colspan="1" rowspan="3">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">195.2</td><td colspan="1" rowspan="1">4.55</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">5.54</td><td colspan="1" rowspan="1">2.8</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">194.7</td><td colspan="1" rowspan="1">4.18</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">6.60</td><td colspan="1" rowspan="1">3.4</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">210.3</td><td colspan="1" rowspan="1">4.82</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">7.00</td><td colspan="1" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="3">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">191.9</td><td colspan="1" rowspan="1">4.42</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">6.72</td><td colspan="1" rowspan="1">3.5</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">199.8</td><td colspan="1" rowspan="1">6.14</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">7.25</td><td colspan="1" rowspan="1">3.6</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">191.9</td><td colspan="1" rowspan="1">5.22</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">6.05</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="4">CommercialControl</td><td colspan="1" rowspan="3">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1484.6</td><td colspan="1" rowspan="1">41.19</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">49.50</td><td colspan="1" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1392.9</td><td colspan="1" rowspan="1">45.11</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">61.56</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1624.9</td><td colspan="1" rowspan="1">40.02</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">63.56</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1475.4</td><td colspan="1" rowspan="1">36.28</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">63.39</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1442.7</td><td colspan="1" rowspan="1">45.91</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">60.02</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">1542.3</td><td colspan="1" rowspan="1">53.36</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">69.39</td><td colspan="1" rowspan="1">4.5</td></tr></table>

Reproducibility analysis was performed using single reagent lots of the Alinity i STAT High Sensitivity Troponin-I reagent, the Alinity i STAT High Sensitivity Troponin-I Calibrators, and the Alinity i STAT High Sensitivity Troponin-I Controls at three sites using 4 replicates per run, 2 runs per day, for 5 days at each site. Below are the between-site and reproducibility precision estimates for the three control materials. Reproducibility includes within-run, between-run, between-day, and between-site variance components.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(ng/L)</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Reproducibility</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LowControl</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>MediumControl</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>197.3</td><td rowspan=1 colspan=1>5.69</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>7.65</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>CommercialControl</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>1493.8</td><td rowspan=1 colspan=1>42.18</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>80.58</td><td rowspan=1 colspan=1>5.2</td></tr></table>

2. Linearity:

Linearity was evaluated using 10 lithium heparin plasma samples ranging in concentrations from $< 2 . 7 \ \mathrm { p g / m L }$ to ${ > } 3 , 6 0 0 \ \mathrm { n g / L }$ . The high samples and the low samples were native and the intermediate samples were prepared by mixing high and low concentration samples. At least four replicates were measured for each sample, and the mean of these replicates was used to calculate the reported results. Deviations from linearity within the claimed range were never observed to be greater than $1 5 \%$ .

# Hook Effect

The sponsor demonstrated that there is no hook effect with the assay up to $5 0 0 { , } 0 0 0 \mathrm { n g / L }$

3. Analytical Specificity/Interference:

Potentially Interfering Endogenous Substances

A study was performed based on the recommendations in the CLSI EP07, 3rd ed. guideline. Each substance was tested at 2 levels of the analyte (approximately $1 5 ~ \mathrm { { n g / L } }$ and $5 0 0 \mathrm { n g / L }$ for bilirubin, total protein, and Intralipid and $1 5 ~ \mathrm { { n g / L } }$ and $2 0 0 \mathrm { n g / L }$ for hemoglobin). Test results from samples spiked with the potential interferent were compared to test results from the control samples lacking the potential interferent. No significant interference (results of the sample with the potential interferent within $\pm 1 0 \%$ of the control sample) was observed at the following concentrations.

<table><tr><td rowspan=1 colspan=1>Endogenous Substance</td><td rowspan=1 colspan=1>Highest Concentration Tested withoutSignificant Interference</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>8.8 g/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr></table>

Interference beyond $\pm 1 0 \%$ was observed at the concentration shown below for the following substance.

<table><tr><td rowspan=1 colspan=1>PotentiallyInterferingSubstance</td><td rowspan=1 colspan=1>InterferentLevel</td><td rowspan=1 colspan=1>AnalyteLevel</td><td rowspan=1 colspan=1>% Interference</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>9.0 g/dL</td><td rowspan=1 colspan=1>500ng/L</td><td rowspan=1 colspan=1>-10.90%</td></tr></table>

Potentially Interfering Drugs and other Compounds

A study was performed based on the recommendations in the CLSI $\mathrm { E P 0 7 } 3 ^ { \mathrm { r d } }$ ed. guideline. Each drug was tested at 2 levels of the analyte (approximately $1 5 ~ \mathrm { { n g / L } }$ and $5 0 0 \mathrm { n g / L } )$ ). Test results from samples spiked with the potential interferent were compared to test results from the control samples lacking the potential interferent. No significant interference (results of the sample with the potential interferent within $\pm 1 0 \%$ of the control sample) was observed at the following concentrations.

<table><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Highest ConcentrationTested WithoutInterference</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">250 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">1000 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Adrenaline</td><td colspan="1" rowspan="1">0.37 pμg/mL</td></tr><tr><td colspan="1" rowspan="1">Allopurinol</td><td colspan="1" rowspan="1">400 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ambroxol</td><td colspan="1" rowspan="1">400 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">1000 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">300 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Atenolol</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Biotin</td><td colspan="1" rowspan="1">3510 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Bivalirudin</td><td colspan="1" rowspan="1">42 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">50 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Carvedilol</td><td colspan="1" rowspan="1">150 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">2500 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cinnarizine</td><td colspan="1" rowspan="1">400 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel</td><td colspan="1" rowspan="1">75 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Cyclosporine</td><td colspan="1" rowspan="1">5 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Diclofenac</td><td colspan="1" rowspan="1">50 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">7.5 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">900 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Doxycycline</td><td colspan="1" rowspan="1">50 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Eptifibatide</td><td colspan="1" rowspan="1">7 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">200 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Fondaparinux</td><td colspan="1" rowspan="1">4 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">400 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Low MW Heparin</td><td colspan="1" rowspan="1">5 U/mL</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">25 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Methylprednisolone</td><td colspan="1" rowspan="1">80 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Metronidazole</td><td colspan="1" rowspan="1">200 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">2 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nitrofurantoin</td><td colspan="1" rowspan="1">64 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Nystatin</td><td colspan="1" rowspan="1">7.5 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Oxytetracycline</td><td colspan="1" rowspan="1">5 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Phenylbutazone</td><td colspan="1" rowspan="1">400 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">100 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">10 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Propranolol</td><td colspan="1" rowspan="1">5 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Quinidine</td><td colspan="1" rowspan="1">20 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Rifampicin</td><td colspan="1" rowspan="1">60 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Salicylic Acid</td><td colspan="1" rowspan="1">600 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Simvastatin</td><td colspan="1" rowspan="1">20 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Sodium Heparin</td><td colspan="1" rowspan="1">8 U/mL</td></tr><tr><td colspan="1" rowspan="1">Streptokinase</td><td colspan="1" rowspan="1">31.3 U/mL</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">75 μg/mL</td></tr><tr><td colspan="1" rowspan="1">TPA</td><td colspan="1" rowspan="1">2.3 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim</td><td colspan="1" rowspan="1">75 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">160 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">30 μg/mL</td></tr></table>

Interference beyond $\pm 1 0 \%$ was observed at the concentration shown below for the following compound.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>InterferentLevel</td><td rowspan=1 colspan=1>AnalyteLevel</td><td rowspan=1 colspan=1>%Interference</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen</td><td rowspan=1 colspan=1>1000mg/dL</td><td rowspan=1 colspan=1>15 ng/L</td><td rowspan=1 colspan=1>24.30%</td></tr></table>

Samples at 3 levels of the analyte (approximately 2.7, 15, and $5 0 0 \mathrm { n g / L }$ ) were spiked with rheumatoid factor (RF) to concentrations of $1 2 0 0 \mathrm { \ : I U / m L }$ and $1 4 9 5 \mathrm { I U / m L }$ and tested with the Alinity i STAT High Sensitivity Troponin-I assay. RF at $1 4 9 5 \mathrm { \ : I U / m L }$ decreased troponin values up to $- 1 8 . 9 \%$ .

Specimens containing human anti-mouse antibodies (HAMA) were evaluated at 3 levels of the analyte (approximately 2.7, 15, and $5 0 0 \mathrm { n g / L } )$ with the Alinity i STAT High Sensitivity Troponin-I assay. HAMA at $2 2 5 ~ \mathrm { { n g / m L } }$ decreased troponin values up to $- 1 1 . 0 \%$ .

# Cross Reactants

A study was performed based on guidance from CLSI EP07, 3rd ed. Samples with cTnI target concentrations of 2.3, 15, and $5 0 0 \mathrm { n g / L }$ containing the cross-reactants at the concentrations listed below were tested with the Alinity i STAT High Sensitivity Troponin-I assay. Test results from samples spiked with the potential interferent were compared to test results from the control samples lacking the potential interferent. There was no observed cross-reactivity at the concentrations tested below.

<table><tr><td rowspan=1 colspan=1>Potential Cross-ReactingSubstance</td><td rowspan=1 colspan=1>Highest ConcentrationTested (ng/L)</td></tr><tr><td rowspan=1 colspan=1>Actin</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>CardiacTroponin C</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>CardiacTroponin T</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>CK-MB</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>Myoglobin</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>Myosin</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>Skeletal Troponin I</td><td rowspan=1 colspan=1>1,000,000</td></tr><tr><td rowspan=1 colspan=1>Tropomyosin</td><td rowspan=1 colspan=1>1,000,000</td></tr></table>

The following additional interferences are described in the labeling:

Troponin autoantibodies have been reported to be present in approximately $10 \%$ to $20 \%$ of patients presenting to the emergency department (ED) and may lead to falsely low troponin assay results and delay in treatment of acute coronary syndrome (ACS). Therefore, a test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.

# Limitations

The following limitations are included in the labeling:

The Alinity i STAT High Sensitivity Troponin-I assay is susceptible to interference effects from total protein $> 8 . 8 ~ \mathrm { g } / \mathrm { d L }$ . Total protein from 9.0 to $1 2 . 0 \ : \mathrm { g / d L }$ decreased troponin values at $5 0 0 \mathrm { n g / L }$ by up to $- 1 6 . 3 \%$ .

Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show depressed values when tested with assay kits such as Alinity i STAT High Sensitivity Troponin-I that employ mouse monoclonal antibodies. Additional information may be required for diagnosis.

Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference, and anomalous values may be observed. Additional information may be required for diagnosis.

The Alinity i STAT High Sensitivity Troponin-I assay is susceptible to interference effects from HAMA $> 1 5 0 ~ \mathrm { n g / m L }$ . HAMA at $2 2 5 ~ \mathrm { { n g / m L } }$ decreased troponin values up to $- 1 1 . 0 \%$ .

The Alinity i STAT High Sensitivity Troponin-I assay is susceptible to interference effects from $\mathrm { R F } > 1 2 0 0 \mathrm { I U } / \mathrm { m L }$ . RF at $1 4 9 5 \mathrm { I U / m L }$ decreased troponin values up to $- 1 8 . 9 \%$ .

Although the Alinity i STAT High Sensitivity Troponin-I assay is specifically designed to minimize the effects of HAMA, heterophilic antibodies, and RF, assay results may be impacted by these proteins.

Specimens from individuals with elevated levels of fibrinogen may demonstrate falsely elevated values.

4. Assay Reportable Range:

2.7 to 3600.0 ng/L (ng/L) cTnI

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability:

The Abbott Alinity i STAT High Sensitivity Troponin-I is traceable to the National Institute of Standards and Technology (NIST) Standard Reference Material SRM2921. The sponsor’s traceability scheme was reviewed and found acceptable.

6. Detection Limit:

Limit of Blank (LoB) Test Protocol

The LoB was determined as described in the CLSI EP17-A2 guideline. Testing was performed using 4 sets of 4 zero-analyte samples tested with 5 replicates on 5 runs over the course of 3 days. Testing was performed using 2 reagent lots and 1 instrument. Sixty determinations were obtained for each reagent lot/instrument combination. LoB was calculated using non-parametric analysis. The largest estimate across all reagent lotinstrument combinations tested was $0 . 0 \mathrm { n g / L }$ .

The LoD was determined following the recommendations in the CLSI EP17-A2 guideline. Testing was performed using 2 reagent lots and 2 instruments. For each lot and instrument combination, at least 5 native low-analyte lithium heparin plasma samples were tested over at least 3 days, with 12 replicates per sample.

The parametric approach described in EP17-A2 was followed to determine the LoD. The largest estimate across all reagent lot-instrument combinations tested was $0 . 9 \mathrm { n g / L }$ .

Limit of Quantitation (LoQ) Protocol

The LoQ was determined as the analyte level with a within-lab CV of $\leq 2 0 \%$ following the recommendations in the CLSI EP17-A2 guideline. Testing was completed using the same parameters and sampling plan as described above in the LoD Test Protocol. For each reagent lot-instrument combination, the within-laboratory precision for each sample, expressed as $\% C V$ , was plotted against the mean concentration obtained for each sample. LoQ was determined by this precision profile as the concentration where the $\% C V$ was less than $20 \%$ . The largest estimate across all reagent lot-instrument combinations tested was $2 . 7 \mathrm { n g / L }$

The sponsor claims a LoB of $0 . 0 \mathrm { n g / L }$ , and LoD of $0 . 9 \mathrm { n g / L }$ , and an LoQ of $2 . 7 \mathrm { n g / L }$

# 7. Assay Cut-Off:

See Clinical Cut-off Section below

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Not applicable

2. Matrix Comparison:

A tube type comparison study was carried out following guidance from EP35, $1 ^ { \mathrm { s t } }$ Edition on the Alinity i STAT High Sensitivity Troponin-I assay to determine if samples collected in lithium heparin and lithium heparin separator blood collection tubes are equivalent. At least 40 fresh samples were collected in each tube type and then supplemented with native heparin plasma samples to spike concentrations ranging from $2 . 7 \mathrm { n g / L }$ to ${ 3 , 5 0 0 \mathrm { n g / L } }$ . The results indicate concentrations of samples are equivalent when heparin plasma is collected in lithium heparin and lithium heparin separator blood collection tubes.

# C Clinical Studies:

# 1. Clinical Sensitivity:

A multi-center prospective study was performed to assess diagnostic accuracy of the Alinity i STAT High Sensitivity Troponin-I assay. Specimens were collected at 23 emergency departments (EDs) from diverse locations within the US (i.e., rural and urban, small and

large, research and non-research) from 6171 subjects presenting to the ED with chest discomfort or equivalent ischemic symptoms consistent with acute coronary syndrome. The specimen collection sites represented geographically diverse EDs associated with primary care hospitals and medical centers, reflecting regional, urban, and rural patient populations. All subject diagnoses were adjudicated by a panel of board-certified cardiologists based on the third universal definition of MI. The sample collection times were at 0 – 1 hour from presentation to the ED and at the following time-point relative to the time from presentation: 1 – 3 hours, 3 – 6 hours, and ${ \ge } 6$ hours. Investigators and adjudicators were blinded to the Alinity i STAT High Sensitivity Troponin-I assay device’s results. Adjudicators were also blinded to site diagnoses. The observed MI prevalence in this study was $7 . 0 \%$ .

The specimens were collected in lithium heparin or lithium heparin separator tubes and tested within 8 hours of sample collection. The specimens were evaluated using the Alinity i STAT High Sensitivity Troponin-I assay. The results were analyzed using the serial sampling time points collected as part of the ED visit.

The sensitivity and specificity results using the overall 99th percentile cutoff $( 2 7 { \mathrm { n g / L } } )$ are summarized in the following table.

<table><tr><td rowspan=2 colspan=1>Sex</td><td rowspan=2 colspan=1>Time Point</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=2>Specificity</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=4 colspan=1>Female</td><td rowspan=1 colspan=1>0 to &lt; 1 Hours</td><td rowspan=1 colspan=1>1,574</td><td rowspan=1 colspan=1>78.43(80/102)</td><td rowspan=1 colspan=1>69.50 -85.30</td><td rowspan=1 colspan=1>89.95(1324/1472)</td><td rowspan=1 colspan=1>88.30 -91.38</td></tr><tr><td rowspan=1 colspan=1>1 to &lt; 3 Hours</td><td rowspan=1 colspan=1>841</td><td rowspan=1 colspan=1>91.49(43/47)</td><td rowspan=1 colspan=1>80.07 -96.64</td><td rowspan=1 colspan=1>92.57(735/794)</td><td rowspan=1 colspan=1>90.53 -94.20</td></tr><tr><td rowspan=1 colspan=1>3 to &lt; 6 Hours</td><td rowspan=1 colspan=1>854</td><td rowspan=1 colspan=1>93.85(61/65)</td><td rowspan=1 colspan=1>85.22 -97.58</td><td rowspan=1 colspan=1>88.34(697/789)</td><td rowspan=1 colspan=1>85.91 -90.40</td></tr><tr><td rowspan=1 colspan=1>≥ 6 Hours</td><td rowspan=1 colspan=1>284</td><td rowspan=1 colspan=1>94.44(51/54)</td><td rowspan=1 colspan=1>84.89 -98.09</td><td rowspan=1 colspan=1>75.65(174/230)</td><td rowspan=1 colspan=1>69.71 -80.75</td></tr><tr><td rowspan=4 colspan=1>Male</td><td rowspan=1 colspan=1>0 to &lt; 1 Hours</td><td rowspan=1 colspan=1>2,917</td><td rowspan=1 colspan=1>76.45(198/259)</td><td rowspan=1 colspan=1>70.92 -81.21</td><td rowspan=1 colspan=1>85.82(2281/2658)</td><td rowspan=1 colspan=1>84.44 -87.09</td></tr><tr><td rowspan=1 colspan=1>1 to &lt; 3 Hours</td><td rowspan=1 colspan=1>1,339</td><td rowspan=1 colspan=1>91.67(77/84)</td><td rowspan=1 colspan=1>83.78 -95.90</td><td rowspan=1 colspan=1>85.02(1067/1255)</td><td rowspan=1 colspan=1>82.94 -86.89</td></tr><tr><td rowspan=1 colspan=1>3 to &lt; 6 Hours</td><td rowspan=1 colspan=1>1,480</td><td rowspan=1 colspan=1>93.46(143/153)</td><td rowspan=1 colspan=1>88.39 -96.41</td><td rowspan=1 colspan=1>80.71(1071/1327)</td><td rowspan=1 colspan=1>78.50 -82.74</td></tr><tr><td rowspan=1 colspan=1>≥ 6 Hours</td><td rowspan=1 colspan=1>576</td><td rowspan=1 colspan=1>94.44(119/126)</td><td rowspan=1 colspan=1>88.98 -97.28</td><td rowspan=1 colspan=1>66.44(299/450)</td><td rowspan=1 colspan=1>61.96 -70.65</td></tr></table>

The positive predictive value (PPV) and negative predictive value (NPV) results using the overall 99th percentile cutoff $( 2 7 { \mathrm { n g / L } } )$ are summarized in the following table.

<table><tr><td colspan="1" rowspan="2">Sex</td><td colspan="1" rowspan="2">TimePoint</td><td colspan="1" rowspan="2">n</td><td colspan="2" rowspan="1">PPV</td><td colspan="2" rowspan="1">NPV</td></tr><tr><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="2">Female</td><td colspan="1" rowspan="1">0 to &lt; 1Hours</td><td colspan="1" rowspan="1">1,574</td><td colspan="1" rowspan="1">35.09(80/228)</td><td colspan="1" rowspan="1">29.19 -41.48</td><td colspan="1" rowspan="1">98.37(1324/1346)</td><td colspan="1" rowspan="1">97.54 -98.92</td></tr><tr><td colspan="1" rowspan="1">1 to &lt; 3Hours</td><td colspan="1" rowspan="1">841</td><td colspan="1" rowspan="1">42.16(43/102)</td><td colspan="1" rowspan="1">33.03 -51.85</td><td colspan="1" rowspan="1">99.46(735/739)</td><td colspan="1" rowspan="1">98.62 -99.79</td></tr><tr><td colspan="1" rowspan="2">−</td><td colspan="1" rowspan="1">3 to &lt; 6Hours</td><td colspan="1" rowspan="1">854</td><td colspan="1" rowspan="1">39.87(61/153)</td><td colspan="1" rowspan="1">32.45 -47.78</td><td colspan="1" rowspan="1">99.43(697/701)</td><td colspan="1" rowspan="1">98.54 -99.78</td></tr><tr><td colspan="1" rowspan="1">≥6Hours</td><td colspan="1" rowspan="1">284</td><td colspan="1" rowspan="1">47.66(51/107)</td><td colspan="1" rowspan="1">38.45 -57.04</td><td colspan="1" rowspan="1">98.31(174/177)</td><td colspan="1" rowspan="1">95.14 -99.42</td></tr><tr><td colspan="1" rowspan="4">Male</td><td colspan="1" rowspan="1">0 to &lt; 1Hours</td><td colspan="1" rowspan="1">2,917</td><td colspan="1" rowspan="1">34.43(198/575)</td><td colspan="1" rowspan="1">30.67 -38.41</td><td colspan="1" rowspan="1">97.40(2281/2342)</td><td colspan="1" rowspan="1">96.67 -97.97</td></tr><tr><td colspan="1" rowspan="1">1 to &lt;3Hours</td><td colspan="1" rowspan="1">1,339</td><td colspan="1" rowspan="1">29.06(77/265)</td><td colspan="1" rowspan="1">23.92 -34.79</td><td colspan="1" rowspan="1">99.35(1067/1074)</td><td colspan="1" rowspan="1">98.66 -99.68</td></tr><tr><td colspan="1" rowspan="1">3 to &lt; 6Hours</td><td colspan="1" rowspan="1">1,480</td><td colspan="1" rowspan="1">35.84(143/399)</td><td colspan="1" rowspan="1">31.29 -40.66</td><td colspan="1" rowspan="1">99.07(1071/1081)</td><td colspan="1" rowspan="1">98.31 -99.50</td></tr><tr><td colspan="1" rowspan="1">≥6Hours</td><td colspan="1" rowspan="1">576</td><td colspan="1" rowspan="1">44.07(119/270)</td><td colspan="1" rowspan="1">38.28 -50.04</td><td colspan="1" rowspan="1">97.71(299/306)</td><td colspan="1" rowspan="1">95.35 -98.89</td></tr></table>

An analysis for both females and males was performed using the sex-specific 99th percentile cutoffs (female $1 4 ~ \mathrm { { n g / L } }$ , male $3 5 \mathrm { n g / L } )$ ). The sensitivity and specificity results are summarized in the following table.

<table><tr><td rowspan=2 colspan=1>Cutoff(ng/L)</td><td rowspan=2 colspan=1>TimePoint</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=2>Specificity</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=4 colspan=1>14(Femaleonly)</td><td rowspan=1 colspan=1>0 to &lt; 1Hours</td><td rowspan=1 colspan=1>1,574</td><td rowspan=1 colspan=1>85.29(87/102)</td><td rowspan=1 colspan=1>77.15 -90.88</td><td rowspan=1 colspan=1>84.04(1237/1472)</td><td rowspan=1 colspan=1>82.08 -85.82</td></tr><tr><td rowspan=1 colspan=1>1 to &lt; 3Hours</td><td rowspan=1 colspan=1>841</td><td rowspan=1 colspan=1>93.62(44/47)</td><td rowspan=1 colspan=1>82.84 -97.81</td><td rowspan=1 colspan=1>85.64(680/794)</td><td rowspan=1 colspan=1>83.03 -87.91</td></tr><tr><td rowspan=1 colspan=1>3 to &lt; 6Hours</td><td rowspan=1 colspan=1>854</td><td rowspan=1 colspan=1>98.46(64/65)</td><td rowspan=1 colspan=1>91.79 -99.73</td><td rowspan=1 colspan=1>82.00(647/789)</td><td rowspan=1 colspan=1>79.17 -84.53</td></tr><tr><td rowspan=1 colspan=1>≥6Hours</td><td rowspan=1 colspan=1>284</td><td rowspan=1 colspan=1>98.15(53/54)</td><td rowspan=1 colspan=1>90.23 -99.67</td><td rowspan=1 colspan=1>69.13(159/230)</td><td rowspan=1 colspan=1>62.89 -74.75</td></tr><tr><td rowspan=4 colspan=1>35(Maleonly)</td><td rowspan=1 colspan=1>0 to &lt; 1Hours</td><td rowspan=1 colspan=1>2,917</td><td rowspan=1 colspan=1>72.20(187/259)</td><td rowspan=1 colspan=1>66.45 -77.30</td><td rowspan=1 colspan=1>88.98(2365/2658)</td><td rowspan=1 colspan=1>87.73 -90.11</td></tr><tr><td rowspan=1 colspan=1>1 to &lt; 3Hours</td><td rowspan=1 colspan=1>1,339</td><td rowspan=1 colspan=1>89.29(75/84)</td><td rowspan=1 colspan=1>80.88 -94.26</td><td rowspan=1 colspan=1>88.29(1108/1255)</td><td rowspan=1 colspan=1>86.39 -89.95</td></tr><tr><td rowspan=1 colspan=1>3 to &lt; 6Hours</td><td rowspan=1 colspan=1>1,480</td><td rowspan=1 colspan=1>90.85(139/153)</td><td rowspan=1 colspan=1>85.23 -94.47</td><td rowspan=1 colspan=1>84.33(1119/1327)</td><td rowspan=1 colspan=1>82.27 -86.18</td></tr><tr><td rowspan=1 colspan=1>≥6Hours</td><td rowspan=1 colspan=1>576</td><td rowspan=1 colspan=1>92.06(116/126)</td><td rowspan=1 colspan=1>86.01 -95.63</td><td rowspan=1 colspan=1>74.22(334/450)</td><td rowspan=1 colspan=1>69.99 -78.05</td></tr></table>

An analysis for both females and males was performed using the sex-specific 99th percentile cutoffs (female $1 4 ~ \mathrm { { n g / L } }$ , male $3 5 \mathrm { n g / L }$ ). The PPV and NPV results are summarized in the following table.

<table><tr><td colspan="1" rowspan="2">Cutoff(ng/L)</td><td colspan="1" rowspan="2">TimePoint</td><td colspan="1" rowspan="2">n</td><td colspan="2" rowspan="1">PPV</td><td colspan="2" rowspan="1">NPV</td></tr><tr><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="2">14(Femaleonly)</td><td colspan="1" rowspan="1">0 to &lt; 1Hours</td><td colspan="1" rowspan="1">1,574</td><td colspan="1" rowspan="1">27.02(87/322)</td><td colspan="1" rowspan="1">22.46 -32.12</td><td colspan="1" rowspan="1">98.80(1237/1252)</td><td colspan="1" rowspan="1">98.03 -99.27</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">841</td><td colspan="1" rowspan="1">27.85</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">99.56</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="1">1 to &lt; 3Hours</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(44/158)</td><td colspan="1" rowspan="1">21.45 -35.30</td><td colspan="1" rowspan="1">(680/683)</td><td colspan="1" rowspan="1">98.72 -99.85</td></tr><tr><td colspan="1" rowspan="1">3 to &lt; 6Hours</td><td colspan="1" rowspan="1">854</td><td colspan="1" rowspan="1">31.07(64/206)</td><td colspan="1" rowspan="1">25.14 -37.69</td><td colspan="1" rowspan="1">99.85(647/648)</td><td colspan="1" rowspan="1">99.13 -99.97</td></tr><tr><td colspan="1" rowspan="1">≥ 6Hours</td><td colspan="1" rowspan="1">284</td><td colspan="1" rowspan="1">42.74(53/124)</td><td colspan="1" rowspan="1">34.38 -51.54</td><td colspan="1" rowspan="1">99.38(159/160)</td><td colspan="1" rowspan="1">96.55 -99.89</td></tr><tr><td colspan="1" rowspan="4">35(Maleonly)</td><td colspan="1" rowspan="1">0 to &lt; 1Hours</td><td colspan="1" rowspan="1">2,917</td><td colspan="1" rowspan="1">38.96(187/480)</td><td colspan="1" rowspan="1">34.70 -43.39</td><td colspan="1" rowspan="1">97.05(2365/2437)</td><td colspan="1" rowspan="1">96.30 -97.65</td></tr><tr><td colspan="1" rowspan="1">1 to &lt; 3Hours</td><td colspan="1" rowspan="1">1,339</td><td colspan="1" rowspan="1">33.78(75/222)</td><td colspan="1" rowspan="1">27.88 -40.23</td><td colspan="1" rowspan="1">99.19(1108/1117)</td><td colspan="1" rowspan="1">98.48 -99.58</td></tr><tr><td colspan="1" rowspan="1">3 to &lt; 6Hours</td><td colspan="1" rowspan="1">1,480</td><td colspan="1" rowspan="1">40.06(139/347)</td><td colspan="1" rowspan="1">35.04 -45.30</td><td colspan="1" rowspan="1">98.76(1119/1133)</td><td colspan="1" rowspan="1">97.94 -99.26</td></tr><tr><td colspan="1" rowspan="1">≥6Hours</td><td colspan="1" rowspan="1">576</td><td colspan="1" rowspan="1">50.00(116/232)</td><td colspan="1" rowspan="1">43.62 -56.38</td><td colspan="1" rowspan="1">97.09(334/344)</td><td colspan="1" rowspan="1">94.73 -98.41</td></tr></table>

The sponsor provided the following information in their labeling:

When using the female cutoff of $1 4 ~ \mathrm { { n g / L } }$ , the lower bound of the $9 5 \%$ CI for the PPV was as low as $2 1 . 4 5 \%$ . Taking into consideration the lower bound of the $9 5 \%$ CI, up to $7 7 . 5 4 \%$ (at 0 to $< 1$ hour), $7 8 . 5 5 \%$ (at 1 to $< 3$ hours), $7 4 . 8 6 \%$ (at 3 to $< 6$ hours), and $6 5 . 6 2 \%$ (at $\geq 6$ hours) of positive troponin results could come from females that are not having an MI. When using the overall cutoff of $2 7 { \mathrm { n g / L } }$ , the lower bound of the $9 5 \%$ CI for PPV was as low as $2 9 . 1 9 \%$ . Taking into consideration the lower bound of the $9 5 \%$ CI, up to $7 0 . 8 1 \%$ (at 0 to $< 1$ hour), $6 6 . 9 7 \%$ (at 1 to $< 3$ hours), $6 7 . 5 5 \%$ (at 3 to $< 6$ hours), and $6 1 . 5 5 \%$ $\mathrm { a t } \geq 6$ hours) of positive troponin results could come from females that are not having an MI. Troponin results should always be used in conjunction with clinical data, signs, and symptoms.

When using the male cutoff of $3 5 \mathrm { n g / L }$ , the lower bound of the $9 5 \%$ CI for the PPV was as low as $2 7 . 8 8 \%$ . Taking into consideration the lower bound of the $9 5 \%$ CI, up to $6 5 . 3 0 \%$ (at 0 to $< 1$ hour), $7 2 . 1 2 \%$ (at 1 to $< 3$ hours), $6 4 . 9 6 \%$ (at 3 to $< 6$ hours), and $5 6 . 3 8 \%$ (at $\geq 6$ hours) of positive troponin results could come from males that are not having an MI. When using the overall cutoff of $2 7 { \mathrm { n g / L } }$ , the lower bound of the $9 5 \%$ CI for PPV was as low as $2 3 . 9 2 \%$ . Taking into consideration the lower bound of the $9 5 \%$ CI, up to $6 9 . 3 3 \%$ (at 0 to $< 1$ hour), $7 6 . 0 8 \%$ (at 1 to $< 3$ hours), $6 8 . 7 1 \%$ (at 3 to $< 6$ hours), and $6 1 . 7 2 \%$ $\mathrm { a t } \geq 6$ hours) of positive troponin results could come from males that are not having an MI. Troponin results should always be used in conjunction with clinical data, signs, and symptoms.

In the Alinity i STAT High Sensitivity Troponin-I clinical study, the percent of false negatives for males using the sex-specific cutoff $( 3 5 \mathrm { n g / L } )$ was up to $1 . 6 3 \%$ higher when compared to the false negative rate for males when using the overall cutoff of $2 7 { \mathrm { n g / L } }$ . When using the male cutoff of $3 5 \mathrm { n g / L }$ , $8 . 1 2 \%$ of males with MI had non elevated Alinity i STAT High Sensitivity Troponin-I test results. When using the overall cutoff of $2 7 { \mathrm { n g / L } }$ , $6 . 4 9 \%$ of males with MI had non-elevated Alinity i STAT High Sensitivity Troponin-I test results. Troponin results should always be used in conjunction with clinical data, signs, and symptoms.

In the Alinity i STAT High Sensitivity Troponin-I clinical study, the percent of false negatives for females using the sex-specific cutoff $( 1 4 \mathrm { n g / L } )$ was up to $2 . 4 1 \%$ lower when compared to the false negative rate for females when using the overall cutoff of $2 7 { \mathrm { n g / L } }$ . When using the female cutoff of $1 4 ~ \mathrm { { n g / L } }$ , $5 . 6 5 \%$ of females with MI had non-elevated Alinity i STAT High Sensitivity Troponin-I test results. When using the overall cutoff of 27 $\mathrm { n g / L }$ , $8 . 0 6 \%$ of females with MI had non-elevated Alinity i STAT High Sensitivity TroponinI test results. Troponin results should always be used in conjunction with clinical data, signs, and symptoms.

The following limitations are in the labeling regarding the clinical performance of this device.

Using the established overall 99th percentile $( 2 7 { \mathrm { n g / L } } )$ , the lower end of the $9 5 \%$ confidence interval (CI) for positive predictive value (PPV) for female subjects was as low as $2 9 . 1 9 \%$ , and for male subjects was as low as $2 3 . 9 2 \%$ in the clinical validation study. Up to $7 0 . 8 1 \%$ and $7 6 . 0 8 \%$ of positive troponin results could come from females and males, respectively, without an MI.

Using the established sex specific 99th percentiles in the same study (female $1 4 ~ \mathrm { { n g / L } }$ , male $3 5 \mathrm { n g / L } )$ , the lower end of the $9 5 \%$ CI for PPV for female subjects was as low as $2 1 . 4 5 \%$ and for male subjects was as low as $2 7 . 8 8 \%$ . Up to $7 8 . 5 5 \%$ and $7 2 . 1 2 \%$ of positive troponin results could come from females and males, respectively, without an MI.

False negative rates using the overall cutoff for females and sex-specific cutoff for males were higher compared to the false negative rates using the sex-specific cutoff for females and overall cutoff for males. Refer to the SPECIFIC PERFORMANCE CHARACTERISTICS, Clinical Results section of this package insert.

# 2. Clinical Specificity:

See Clinical Sensitivity above (Section VII. C. 1.).

# D Clinical Cut-Off:

The cut-offs for this assay were determined based on the 99th percentile upper reference limit in apparently healthy adults. Please see Expected Values/Reference Range below (Section VII. E.) for the determination of the clinical cut-offs.

# E Expected Values/Reference Range:

A reference range study was conducted based on guidance from CLSI EP28-A3c. Specimens were collected from 1531 apparently healthy individuals in a US population with the following levels of biomarkers:

<table><tr><td rowspan=1 colspan=1>Biomarker</td><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>Female</td></tr><tr><td rowspan=1 colspan=1>Cardiac BNP (pg/mL)</td><td rowspan=1 colspan=1>≤ 25</td><td rowspan=1 colspan=1>≤ 40</td></tr><tr><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=2>≤6</td></tr><tr><td rowspan=1 colspan=1>GFR (mL/min/1.73 m2²)</td><td rowspan=1 colspan=2>≥ 60</td></tr></table>

Each specimen was stored frozen, thawed, and evaluated in replicates of one using the Abbott ARCHITECT STAT High Sensitivity Troponin-I assay. The $9 9 ^ { \mathrm { t h } }$ percentiles described in the following table for this population were determined using the robust statistical method described in CLSI EP28-A3c.

<table><tr><td rowspan=1 colspan=1>Apparently HealthyPopulation</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Age Range(years)</td><td rowspan=1 colspan=1>99th Percentile(ng/L)</td><td rowspan=1 colspan=1>90% CI(ng/L)</td></tr><tr><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>763</td><td rowspan=1 colspan=1>21-75</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>[12, 17]</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>766</td><td rowspan=1 colspan=1>21-73</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>[27, 44]</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>1531</td><td rowspan=1 colspan=1>21-75</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>[22, 32]</td></tr></table>

# VIII Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.